Meenhard Herlyn, DVM, DSc

The Wistar Institute

Dr. Herlyn's presentation is titled: New Opportunities For Melanoma Research

• It is specific to melanoma and recognizes the need for additional melanoma research funding
• Addresses the relevance of studying genetic changes in cancer cells and the impact on determining therapy.
• Specifies new drugs in the pipeline
• Highlights the value of using a combination of drugs
• Describes the value of killing stem and early daughter cells as predictors of treatment success.

Mr. Edward Long, Vice President of Congressional Relations

Capitol Associates will share updates on NMA Public Policy Activities and Priorities